Cited by 1,626Cholangiocarcinoma and Gallbladder Cancer StudiesPediatric Hepatobiliary Diseases and TreatmentsLiver Diseases and Immunity

The DOI matches its Crossref record; 175 of the 175 references it cites were found in a registry or an index.

Cholangiocarcinoma — evolving concepts and therapeutic strategies

Open access

Ilyas, Sumera I., Khan, Shahid A., Hallemeier, Christopher L., Kelley, Robin K., Gores, Gregory J.·2018·Nature Reviews Clinical Oncology

DOI 10.1038/nrclinonc.2017.157PMC PMC5819599

Open this paper in CoChat — free account

Abstract

Cholangiocarcinoma is a disease entity comprising diverse epithelial tumours with features of cholangiocyte differentiation: cholangiocarcinomas are categorized according to anatomical location as intrahepatic (iCCA), perihilar (pCCA), or distal (dCCA). Each subtype has a distinct epidemiology, biology, prognosis, and strategy for clinical management. The incidence of cholangiocarcinoma, particularly iCCA, has increased globally over the past few decades. Surgical resection remains the mainstay of potentially curative treatment for all three disease subtypes, whereas liver transplantation after neoadjuvant chemoradiation is restricted to a subset of patients with early stage pCCA. For patients with advanced-stage or unresectable disease, locoregional and systemic chemotherapeutics are the primary treatment options. Improvements in external-beam radiation therapy have facilitated the treatment of cholangiocarcinoma. Moreover, advances in comprehensive whole-exome and transcriptome sequencing have defined the genetic landscape of each cholangiocarcinoma subtype. Accordingly, promising molecular targets for precision medicine have been identified, and are being evaluated in clinical trials, including those exploring immunotherapy. Biomarker-driven trials, in which patients are stratified according to anatomical cholangiocarcinoma subtype and genetic aberrations, will be essential in the development of targeted therapies. Targeting the rich tumour stroma of cholangiocarcinoma in conjunction with targeted therapies might also be useful. Herein, we review the evolving developments in the epidemiology, pathogenesis, and management of cholangiocarcinoma.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/nrclinonc.2017.157

Cites

175 of 175 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
Valle, J. W., Wasan, H. S., Palmer, D. H., Cunningham, D., Anthoney, A., Maraveyas, A., Madhusudan, S., Iveson, T. J., Hughes, S., Pereira, S. P., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0908721 · Cited by 4,423
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J. M., Desrichard, A., Walsh, L. A., Postow, M. A., Wong, P., Ho, T. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406498 · Cited by 4,286
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
El-Khoueiry, A. B., Sangro, B., Yau, T., Crocenzi, T. S., Kudo, M., Hsu, C., Kim, T.-Y., Choo, S.-P., Trojan, J., Welling, T. H., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31046-2 · Cited by 4,280
Tumour-associated macrophages as treatment targets in oncology
Mantovani, A., Marchesi, F., Malesci, A., Laghi, L., & Allavena, P. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.217 · Cited by 4,157
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
Rosenberg, J. E., Hoffman-Censits, J., Powles, T., van der Heijden, M. S., Balar, A. V., Necchi, A., Dawson, N., O'Donnell, P. H., Balmanoukian, A., Loriot, Y., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00561-4 · Cited by 3,669
Cancer epigenetics: from mechanism to therapy
Dawson, M. A., & Kouzarides, T. (2012) · Cell · doi:10.1016/j.cell.2012.06.013 · Cited by 3,203

Show all 175 references

Sorted by citations

Items 201–300 of 1,001

Platelet-derived PDGF promotes the invasion and metastasis of cholangiocarcinoma by upregulating MMP2/MMP9 expression and inducing EMT via the p38/MAPK signalling pathway.
Pan, S., Hu, Y., Hu, M., Jian, H., Chen, M., Gan, L., Zheng, P., He, Y., & Wang, J. (2020) · PubMed · Cited by 38
The new insight of treatment in Cholangiocarcinoma
Li, Y., Song, Y., & Liu, S. (2022) · Journal of Cancer · doi:10.7150/jca.68264 · Cited by 40
Pathological, molecular, and clinical characteristics of cholangiocarcinoma: A comprehensive review
Vij, M., Puri, Y., Rammohan, A., Gowripriya, G., Rajalingam, R., Kaliamoorthy, I., & Rela, M. (2022) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v14.i3.607 · Cited by 40
Adjuvant and neoadjuvant therapy for biliary tract cancer: a review of clinical trials
Nara, S., Esaki, M., Ban, D., Takamoto, T., Shimada, K., Ioka, T., Okusaka, T., Ishii, H., & Furuse, J. (2020) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyaa170 · Cited by 39
Association of Diabetes Mellitus and Cholangiocarcinoma: Update of Evidence and the Effects of Antidiabetic Medication
Saengboonmee, C., Seubwai, W., Lert-itthiporn, W., Sanlung, T., & Wongkham, S. (2020) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2020.09.008 · Cited by 40
Targeting the tumor microenvironment in cholangiocarcinoma: implications for therapy
Wang, J., & Ilyas, S. I. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2021.1865308 · Cited by 38
Self-citation
Intrahepatic cholangiocarcinoma: Evolving strategies in management and treatment
Bragazzi, M. C., Venere, R., Ribichini, E., Covotta, F., Cardinale, V., & Alvaro, D. (2023) · Digestive and Liver Disease · doi:10.1016/j.dld.2023.08.052 · Cited by 39
Fibroblast-Derived Lysyl Oxidase Increases Oxidative Phosphorylation and Stemness in Cholangiocarcinoma
Lewińska, M., Zhuravleva, E., Satriano, L., Martinez, M. B., Bhatt, D. K., Oliveira, D. V. N. P., Antoku, Y., Keggenhoff, F. L., Castven, D., Marquardt, J. U., et al. (2023) · Gastroenterology · doi:10.1053/j.gastro.2023.11.302 · Cited by 38
Management implications of fluorodeoxyglucose positron emission tomography/magnetic resonance in untreated intrahepatic cholangiocarcinoma
Ferrone, C. R., Goyal, L., Qadan, M., Gervais, D. A., Sahani, D. V., Zhu, A. X., Hong, T. S., Blaszkowsky, L. S., Tanabe, K. K., Vangel, M. G., et al. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-04558-3 · Cited by 38
Down-regulation of USP8 Inhibits Cholangiocarcinoma Cell Proliferation and Invasion
Xu, J., Chen, Y., Chen, Y., Shi, G., Lv, S., Cheng, N., Feng, C., Xin, Z., Zhang, L., & Wu, J. (2020) · Cancer Management and Research · doi:10.2147/cmar.s234586 · Cited by 38
Tumor microenvironment in primary liver tumors: A challenging role of natural killer cells
Polidoro, M. A., Mikulak, J., Cazzetta, V., Lleò, A., Mavilio, D., Torzilli, G., & Donadon, M. (2020) · World Journal of Gastroenterology · doi:10.3748/wjg.v26.i33.4900 · Cited by 41
Analysis of bile acid profile in plasma to differentiate cholangiocarcinoma from benign biliary diseases and healthy controls
Zhang, X., Yang, Z., Shi, Z., Zhu, Z., Li, C., Du, Z., Zhang, Y., Wang, Z., Jiao, Z., Tian, X., et al. (2020) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2020.105775 · Cited by 38
New Indications for Liver Transplantation
Zanetto, A., Shalaby, S., Gambato, M., Germani, G., Senzolo, M., Bizzaro, D., Russo, F. P., & Burra, P. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10173867 · Cited by 40
YAP Accelerates Notch-Driven Cholangiocarcinogenesis via mTORC1 in Mice
Lu, X., Peng, B., Chen, G., Pes, G. M., Ribback, S., Ament, C. E., Xu, H., Pal, R. R., Rodrigues, P. M., Bañales, J. M., et al. (2021) · American Journal Of Pathology · doi:10.1016/j.ajpath.2021.05.017 · Cited by 37
Cholangiocarcinoma: Pathologic and Molecular Classification in the Era of Precision Medicine
Gopal, P., Robert, M. E., & Zhang, X. (2023) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2022-0537-ra · Cited by 37
Curcumol Exerts Anticancer Effect in Cholangiocarcinoma Cells via Down-Regulating CDKL3
Zhang, J., Su, G., Tang, Z., Wang, L., Fu, W., Zhao, S., Ba, Y., Bai, B., Yue, P., Lin, Y., et al. (2018) · Frontiers in Physiology · doi:10.3389/fphys.2018.00234 · Cited by 37
PARP Inhibitors in Biliary Tract Cancer: A New Kid on the Block?
Ricci, A. D., Rizzo, A., Bonucci, C., Tober, N., Palloni, A., Mollica, V., Maggio, I., Deserti, M., Tavolari, S., & Brandi, G. (2020) · Medicines · doi:10.3390/medicines7090054 · Cited by 37
The VEGF expression associated with prognosis in patients with intrahepatic cholangiocarcinoma: a systematic review and meta-analysis
Cai, C., Wang, X., Fu, Q., & Chen, A. (2022) · World Journal of Surgical Oncology · doi:10.1186/s12957-022-02511-7 · Cited by 37
KRAS acting through ERK signaling stabilizes PD-L1 via inhibiting autophagy pathway in intrahepatic cholangiocarcinoma
Gao, Z., Chen, J., Li, X.-G., Shi, Y., Tang, Z., Liu, W.-R., Zhang, X., Huang, A., Luo, X., Gao, Q., et al. (2022) · Cancer Cell International · doi:10.1186/s12935-022-02550-w · Cited by 39
Progress in Radiotherapy for Cholangiocarcinoma
Wang, N., Huang, A., Kuang, B., Yu, X., Xiao, Y., & Ma, H. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.868034 · Cited by 38
The m6A writers regulated by the IL-6/STAT3 inflammatory pathway facilitate cancer cell stemness in cholangiocarcinoma
Ye, H., Chen, T., Zeng, Z., He, B., Yang, Q., Pan, Q., Chen, Y., & Wang, W. (2021) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2020.0661 · Cited by 36
BMI1 promotes cholangiocarcinoma progression and correlates with antitumor immunity in an exosome-dependent manner
Liu, Z., Hu, C., Zheng, L., Liu, J., Li, K., Li, X., Wang, Y., Mu, W., Chen, T., Shi, A., et al. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04500-1 · Cited by 37
FGFR Inhibitors in Cholangiocarcinoma—A Novel Yet Primary Approach: Where Do We Stand Now and Where to Head Next in Targeting This Axis?
Chmiel, P., Gęca, K., Rawicz‐Pruszyński, K., Polkowski, W. P., & Skórzewska, M. (2022) · Cells · doi:10.3390/cells11233929 · Cited by 36
Advances in the Diagnosis and Treatment of Patients with Intrahepatic Cholangiocarcinoma
Ejaz, A. M., Cloyd, J. M., & Pawlik, T. M. (2019) · Annals of Surgical Oncology · doi:10.1245/s10434-019-07873-z · Cited by 36
BRD4 degrader ARV-825 produces long-lasting loss of BRD4 protein and exhibits potent efficacy against cholangiocarcinoma cells.
Lu, Q., Ding, X., Huang, T., Zhang, S., Li, Y., Xu, L., Chen, G., Ying, Y., Wang, Y., Feng, Z., et al. (2019) · PubMed Central · Cited by 36
Epidemiology of HPB malignancy in the elderly
Pericleous, M., & Khan, S. A. (2020) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2020.03.222 · Cited by 38
Self-citation
LncRNA MT1JP plays a protective role in intrahepatic cholangiocarcinoma by regulating miR-18a-5p/FBP1 axis
Zhao, W., Zhao, J., Guo, X., Feng, Y., Zhang, B., & Tian, L. (2021) · BMC Cancer · doi:10.1186/s12885-021-07838-0 · Cited by 36
Association between non-alcoholic fatty liver disease and the risk of biliary tract cancers: A South Korean nationwide cohort study
Park, J., Hong, J. Y., Kwon, M., Lee, J., Han, K., Han, I. W., Kang, W., & Park, J. K. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.03.024 · Cited by 37
Atractylodin inhibited the migration and induced autophagy in cholangiocarcinoma cells via PI3K/AKT/mTOR and p38MAPK signalling pathways
Acharya, B., Chai่jaroenkul, W., & Na‐Bangchang, K. (2021) · Journal of Pharmacy and Pharmacology · doi:10.1093/jpp/rgab036 · Cited by 35
The Role of microRNAs in Cholangiocarcinoma
Shi, T., Morishita, A., Kobara, H., & Masaki, T. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22147627 · Cited by 38
Role of sex in liver tumor occurrence and clinical outcomes: A comprehensive review
Toniutto, P., Shalaby, S., Mameli, L., Morisco, F., Gambato, M., Cossiga, V., Guarino, M., Marra, F., Brunetto, M. R., Burra, P., et al. (2023) · Hepatology · doi:10.1097/hep.0000000000000277 · Cited by 37
MUC1 induces the accumulation of Foxp3+ Treg cells in the tumor microenvironment to promote the growth and metastasis of cholangiocarcinoma through the EGFR/PI3K/Akt signaling pathway
Zhang, G., Ge, Z., Zhang, H., & Qiu, L. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110091 · Cited by 35
Dependency of Cholangiocarcinoma on Cyclin D–Dependent Kinase Activity
Sittithumcharee, G., Suppramote, O., Vaeteewoottacharn, K., Sirisuksakun, C., Jamnongsong, S., Laphanuwat, P., Suntiparpluacha, M., Matha, A., Chusorn, P., Buraphat, P., et al. (2019) · Hepatology · doi:10.1002/hep.30704 · Cited by 35
Cholangiocarcinoma miscoding in hepatobiliary centres
Selvadurai, S., Mann, K., Mithra, S., Bridgewater, J. A., Malik, H., & Khan, S. A. (2020) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2020.09.039 · Cited by 35
Self-citation
Is laparoscopic liver resection safe for intrahepatic cholangiocarcinoma? A meta-analysis
Regmi, P., Hu, H., Paudyal, P., Liu, F., Ma, W., Yin, C.-H., Jin, Y., & Li, F.-Y. (2020) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2020.11.310 · Cited by 35
NNMT promotes the progression of intrahepatic cholangiocarcinoma by regulating aerobic glycolysis via the EGFR-STAT3 axis
Lu, S., Ke, S., Wang, C., Xu, Y., Li, Z., Song, K., Bai, M., Zhou, M., Yu, H., Yin, B., et al. (2022) · Oncogenesis · doi:10.1038/s41389-022-00415-5 · Cited by 35
Patient healthcare trajectories of intrahepatic cholangiocarcinoma in France: A nationwide retrospective analysis
Neuzillet, C., Emery, C., Teissier, C., Bouée, S., & Lièvre, A. (2022) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2022.100324 · Cited by 34
The clinical implications and molecular features of intrahepatic cholangiocarcinoma with perineural invasion
Meng, X., Lu, J., Zeng, H., Chen, Z., Guo, X.-J., Gao, C., Pei, Y.-Z., Hu, S., Ye, M., Sun, Q., et al. (2022) · Hepatology International · doi:10.1007/s12072-022-10445-1 · Cited by 34
Biologics, Immunotherapy, and Future Directions in the Treatment of Advanced Cholangiocarcinoma
Saeed, A., Park, R., Al‐Jumayli, M., Al-Rajabi, R. M. T., & Sun, W. (2019) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2019.02.005 · Cited by 34
Tumor Budding in Intrahepatic Cholangiocarcinoma
Tanaka, M. H., Yamauchi, N., Ushiku, T., Shibahara, J., Hayashi, A., Misumi, K., Yasunaga, Y., Morikawa, T., Kokudo, T., Arita, J., et al. (2019) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000001332 · Cited by 34
Pterostilbene, An Active Constituent of Blueberries, Suppresses Proliferation Potential of Human Cholangiocarcinoma via Enhancing the Autophagic Flux
Wang, D., Guo, H., Yang, H., Wang, D., Gao, P., & Wei, W. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01238 · Cited by 34
The Evolving Role of Radiation Therapy in the Treatment of Biliary Tract Cancer
Gkika, E., Hawkins, M., Grosu, A., & Brunner, T. B. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.604387 · Cited by 34
Application of Immune Checkpoint Inhibitors in the Treatment of Cholangiocarcinoma
Zeng, F., & Chen, J.-F. (2021) · Technology in Cancer Research & Treatment · doi:10.1177/15330338211039952 · Cited by 35
Circulating Cell-Free DNA-Based Comprehensive Molecular Analysis of Biliary Tract Cancers Using Next-Generation Sequencing
Csoma, S. L., Bedekovics, J., Veres, G., Árokszállási, A., András, C., Méhes, G., & Mokánszki, A. (2022) · Cancers · doi:10.3390/cancers14010233 · Cited by 35
Radiomics-Based Preoperative Prediction of Lymph Node Metastasis in Intrahepatic Cholangiocarcinoma Using Contrast-Enhanced Computed Tomography
Zhang, S., Huang, S., He, W., Wei, J., Huo, L., Jia, N., Lin, J., Tang, Z., Yuan, Y., Tian, J., et al. (2022) · Annals of Surgical Oncology · doi:10.1245/s10434-022-12028-8 · Cited by 34
CircZNF215 promotes tumor growth and metastasis through inactivation of the PTEN/AKT pathway in intrahepatic cholangiocarcinoma
Liao, W., Du, J., Li, L., Wu, X. Y., Chen, X., Feng, Q., Xu, L., Chen, X., Liao, M., Huang, J., et al. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02699-w · Cited by 38
Major complications and mortality after resection of intrahepatic cholangiocarcinoma: A systematic review and meta-analysis
van Keulen, A., Büttner, S., Erdmann, J. I., Hagendoorn, J., Hoogwater, F. J. H., IJzermans, J. N. M., Neumann, U. P., Polak, W. G., de Jonge, J., Olthof, P. B., et al. (2022) · Surgery · doi:10.1016/j.surg.2022.11.027 · Cited by 33
Molecular profiling and treatment pattern differences between intrahepatic and extrahepatic cholangiocarcinoma
Spencer, K. R., Pappas, L., Baiev, I., Maurer, J. R., Bocobo, A. G., Zhang, K., Jain, A., Armas, A. D. D., Reyes, S., Le, T. M., et al. (2023) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djad046 · Cited by 33
Self-citation
Latest evidence on immunotherapy for cholangiocarcinoma (Review)
Guo, X., & Shen, W. (2020) · Oncology Letters · doi:10.3892/ol.2020.12244 · Cited by 33
Neoadjuvant Chemotherapy for Intrahepatic, Perihilar, and Distal Cholangiocarcinoma: a National Population-Based Comparative Cohort Study
Parente, A., Kamarajah, S. K., Baia, M., Tirotta, F., Manzia, T. M., Hilal, M. A., Pawlik, T. M., White, S. A., & Dahdaleh, F. S. (2023) · Journal of Gastrointestinal Surgery · doi:10.1007/s11605-023-05606-y · Cited by 32
ErBb Family Proteins in Cholangiocarcinoma and Clinical Implications
Jin, W. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9072255 · Cited by 33
HOXD8 hypermethylation as a fully sensitive and specific biomarker for biliary tract cancer detectable in tissue and bile samples
Loi, E., Zavattari, C., Tommasi, A., Moi, L., Canale, M., Pò, A., Sabato, C., Vega-Benedetti, A. F., Ziranu, P., Puzzoni, M., et al. (2022) · British Journal of Cancer · doi:10.1038/s41416-022-01738-1 · Cited by 33
Systemic Treatments with Tyrosine Kinase Inhibitor and Platinum-Based Chemotherapy in Patients with Unresectable or Metastatic Hepatocholangiocarcinoma
Gigante, E., Hobeika, C., Bail, B. L., Paradis, V., Tougeron, D., Lequoy, M., Bouattour, M., Blanc, J., Ganne‐Carrié, N., Tran, H., et al. (2022) · Liver Cancer · doi:10.1159/000525488 · Cited by 32
Revisiting targeted therapy and immunotherapy for advanced cholangiocarcinoma
Du, J., Lv, X., Zhang, Z., Huang, Z., & Zhang, E. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1142690 · Cited by 34
Neoadjuvant therapy in the treatment of hilar cholangiocarcinoma: Review of the literature
Frosio, F., Mocchegiani, F., Conte, G., Bona, E. D., Vecchi, A. L., Nicolini, D., & Vivarelli, M. (2019) · World Journal of Gastrointestinal Surgery · doi:10.4240/wjgs.v11.i6.279 · Cited by 32
Modulation of STAT3 Signaling, Cell Redox Defenses and Cell Cycle Checkpoints by β-Caryophyllene in Cholangiocarcinoma Cells: Possible Mechanisms Accounting for Doxorubicin Chemosensitization and Chemoprevention
Sotto, A. D., Giacomo, S. D., Rubini, E., Macone, A., Gullì, M., Mammola, C. L., Eufemi, M., Mancinelli, R., & Mazzanti, G. (2020) · Cells · doi:10.3390/cells9040858 · Cited by 32
IDH1 Targeting as a New Potential Option for Intrahepatic Cholangiocarcinoma Treatment—Current State and Future Perspectives
Crispo, F., Pietrafesa, M., Condelli, V., Maddalena, F., Bruno, G., Piscazzi, A., Sgambato, A., Esposito, F., & Landriscina, M. (2020) · Molecules · doi:10.3390/molecules25163754 · Cited by 32
HPV-induced Nurr1 promotes cancer aggressiveness, self-renewal, and radioresistance via ERK and AKT signaling in cervical cancer
Wan, P. K.-T., Leung, T. H.-Y., Siu, M. K.-Y., Mo, X.-T., Tang, H. W., Chan, K. K. L., Cheung, A., & Ngan, H. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.09.025 · Cited by 32
Combined Hepatocellular-Cholangiocarcinoma: What the Multidisciplinary Team Should Know
Cutolo, C., Dell’Aversana, F., Fusco, R., Grazzini, G., Chiti, G., Simonetti, I., Bruno, F., Palumbo, P., Pierpaoli, L., Valeri, T., et al. (2022) · Diagnostics · doi:10.3390/diagnostics12040890 · Cited by 34
Biomarkers for response to immunotherapy in hepatobiliary malignancies
Lin, Z., Qin, L., & Chen, J. (2022) · Hepatobiliary & pancreatic diseases international · doi:10.1016/j.hbpd.2022.08.002 · Cited by 31
Long Noncoding RNA H19: A Novel Oncogene in Liver Cancer
Wang, Y., Zeng, J., Chen, W., Fan, J., Hylemon, P. B., & Zhou, H. (2023) · Non-Coding RNA · doi:10.3390/ncrna9020019 · Cited by 31
Correction to: Molecular detection and clinicopathological characteristics of advanced/recurrent biliary tract carcinomas harboring the FGFR2 rearrangements: a prospective observational study (PRELUDE Study)
Maruki, Y., Morizane, C., Arai, Y., Ikeda, M., Ueno, M., Ioka, T., Naganuma, A., Furukawa, M., Mizuno, N., Uwagawa, T., et al. (2020) · Journal of Gastroenterology · doi:10.1007/s00535-020-01755-y · Cited by 31
IDH Inhibitors and Immunotherapy for Biliary Tract Cancer: A Marriage of Convenience?
Brandi, G., & Rizzo, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231810869 · Cited by 30
Cordycepin reprogramming lipid metabolism to block metastasis and EMT via ERO1A/mTOR/SREBP1 axis in cholangiocarcinoma
Zhou, X., Li, Y., Yang, C., Chen, D., Wang, T., Liu, T., Yan, W., Su, Z., Peng, B., & Ren, X. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.121698 · Cited by 30
CircPCNXL2 promotes tumor growth and metastasis by interacting with STRAP to regulate ERK signaling in intrahepatic cholangiocarcinoma
Liu, S., Wang, Y., Wang, T., Shi, K., Fan, S., Li, C., Chen, R., Wang, J., Jiang, W., Zhang, Y., et al. (2024) · Molecular Cancer · doi:10.1186/s12943-024-01950-y · Cited by 31
The scaffold of neutrophil extracellular traps promotes CCA progression and modulates angiogenesis via ITGAV/NFκB
Zhang, C., Wu, D., Dong, B., Liao, G., Yu, Y., Huang, S., Luo, F., Zhang, B., Wu, H., Li, T., et al. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-024-01500-5 · Cited by 32
Enhancement of gemcitabine sensitivity in intrahepatic cholangiocarcinoma through Saikosaponin-a mediated modulation of the p-AKT/BCL-6/ABCA1 axis
Song, F., Wang, C., Wang, T., Tao, Y.-C., Mao, J., Hu, C.-W., Zhang, Y. X., Tang, P., Lu, C., Qing, H.-L., et al. (2024) · Phytomedicine · doi:10.1016/j.phymed.2024.155944 · Cited by 30
Long non-coding RNA EPIC1 promotes cholangiocarcinoma cell growth
Li, Y., Cai, Q., Li, W., Feng, F., & Yang, L. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.08.174 · Cited by 30
Induction of phosphatase shatterproof 2 by evodiamine suppresses the proliferation and invasion of human cholangiocarcinoma
Zhu, B., Zhao, L., Liu, Y., Jin, Y., Feng, J. Q., Zhao, F., Sun, J., Geng, R., & Wei, Y. (2019) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2019.01.012 · Cited by 30
Hepatitis C Virus Infection and Cholangiocarcinoma
Navas, M. C., Glaser, S. S., Dhruv, H., Celinski, S. A., Alpini, G. D., & Meng, F. (2019) · American Journal Of Pathology · doi:10.1016/j.ajpath.2019.01.018 · Cited by 30
Biliary stenting alone versus biliary stenting combined with 125I particles intracavitary irradiation for the treatment of advanced cholangiocarcinoma
Pang, Q., Zhou, L., Hu, X., Wang, Y., Man, Z., Yang, S., Wang, W., Qian, Z., Jin, H., & Liu, H. (2019) · Scientific Reports · doi:10.1038/s41598-019-47791-4 · Cited by 30
A novel circulating tumor cell subpopulation for treatment monitoring and molecular characterization in biliary tract cancer
Reduzzi, C., Vismara, M., Silvestri, M., Celio, L., Niger, M., Peverelli, G., de Braud, F., Daidone, M. G., & Cappelletti, V. (2019) · International Journal of Cancer · doi:10.1002/ijc.32822 · Cited by 30
Key necroptotic proteins are required for Smac mimetic-mediated sensitization of cholangiocarcinoma cells to TNF-α and chemotherapeutic gemcitabine-induced necroptosis
Akara-amornthum, P., Lomphithak, T., Choksi, S., Tohtong, R., & Jitkaew, S. (2020) · PLoS ONE · doi:10.1371/journal.pone.0227454 · Cited by 31
Necroptosis in Cholangiocarcinoma
Sarcognato, S., de Jong, I. E. M., Fabris, L., Cadamuro, M., & Guido, M. (2020) · Cells · doi:10.3390/cells9040982 · Cited by 30
Current management of intrahepatic cholangiocarcinoma: from resection to palliative treatments
Bartolini, I., Risaliti, M., Fortuna, L., Agostini, C., Ringressi, M. N., Taddei, A., & Muiesan, P. (2020) · Radiology and Oncology · doi:10.2478/raon-2020-0045 · Cited by 31
FGFR Inhibitors: Clinical Activity and Development in the Treatment of Cholangiocarcinoma
King, G. T., & Javle, M. M. (2021) · Current Oncology Reports · doi:10.1007/s11912-021-01100-3 · Cited by 30
A Novel Trojan Horse Nanotherapy Strategy Targeting the cPKM‐STMN1/TGFB1 Axis for Effective Treatment of Intrahepatic Cholangiocarcinoma
Chen, Z., Kang, F., Xie, C., Liao, C., Li, G., Wu, Y., Lin, H., Zhu, S., Hu, J., Lin, C., et al. (2023) · Advanced Science · doi:10.1002/advs.202303814 · Cited by 31
Prognostic significance of systemic immune-inflammation index in patients with intrahepatic cholangiocarcinoma undergoing hepatic resection
Li, H., Wang, J., Zhang, M., Ren, B., Li, J., Lin, X., & Wu, H. M. (2020) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v12.i4.467 · Cited by 29
Mitochondria-anchoring and AIE-active photosensitizer for self-monitored cholangiocarcinoma therapy
Zhou, T., Zhu, J., Shang, D., Chai, C., Li, Y., Sun, H., Li, Y., Gao, M., & Li, M. (2020) · Materials Chemistry Frontiers · doi:10.1039/d0qm00503g · Cited by 29
Trends in the Mortality of Biliary Tract Cancers Based on Their Anatomical Site in the United States From 2009 to 2018
Kim, D., Konyn, P., Cholankeril, G. T., Bonham, C. A., & Ahmed, A. (2021) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000001151 · Cited by 29
Comprehensive analysis of genomic mutation signature and tumor mutation burden for prognosis of intrahepatic cholangiocarcinoma
Zhang, R., Li, Q., Fu, J., Jin, Z., Su, J., Zhang, J., Chen, C., Geng, Z., & Zhang, D. (2021) · BMC Cancer · doi:10.1186/s12885-021-07788-7 · Cited by 28
Multimodal molecular imaging evaluation for early diagnosis and prognosis of cholangiocarcinoma
Liu, J., Ren, W. X., & Shu, J. (2022) · Insights into Imaging · doi:10.1186/s13244-021-01147-7 · Cited by 29
Knockout of liver fluke granulin, Ov-grn-1, impedes malignant transformation during chronic infection with Opisthorchis viverrini
Chaiyadet, S., Tangkawattana, S., Smout, M. J., Ittiprasert, W., Mann, V. H., Deenonpoe, R., Arunsan, P., Loukas, A. C., Brindley, P. J., & Laha, T. (2022) · PLoS Pathogens · doi:10.1371/journal.ppat.1010839 · Cited by 30
Liver transplantation in the management of cholangiocarcinoma: Evolution and contemporary advances
Borakati, A., Froghi, F., Bhogal, R. H., & Mavroeidis, V. K. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i13.1969 · Cited by 29
Reprogramming the Intrahepatic Cholangiocarcinoma Immune Microenvironment by Chemotherapy and CTLA-4 Blockade Enhances Anti–PD-1 Therapy
Chen, J., Amoozgar, Z., Liu, X., Aoki, S., Liu, Z., Shin, S. M., Matsui, A., Hernandez, A., Pu, Z., Halvorsen, S. C., et al. (2024) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-23-0486 · Cited by 28
Bintrafusp alfa and chemotherapy as first-line treatment in biliary tract cancer: A randomized phase 2/3 trial
Oh, D., Ikeda, M., Lee, C., Rojas, C., Hsu, C., Kim, J. W., Shen, L., Furuse, J., Park, J. O., Borad, M. J., et al. (2024) · Hepatology · doi:10.1097/hep.0000000000000965 · Cited by 29
Albumin-Bilirubin Grade as a Novel Predictor of Survival in Advanced Extrahepatic Cholangiocarcinoma
Wang, Y., Pang, Q., Jin, H., Zhou, L., Hu, X., Qian, Z., Man, Z., Yang, S., & Liu, H. (2018) · Gastroenterology Research and Practice · doi:10.1155/2018/8902146 · Cited by 28
Establishment and Characterization of a New Intrahepatic Cholangiocarcinoma Cell Line Resistant to Gemcitabine
Varamo, C., Neia, C. P., Ostano, P., Basiricò, M., Raggi, C., Bernabei, P., Venesio, T., Berrino, E., Aglietta, M., Leone, F., et al. (2019) · Cancers · doi:10.3390/cancers11040519 · Cited by 28
Multifaceted Aspects of Metabolic Plasticity in Human Cholangiocarcinoma: An Overview of Current Perspectives
Pastore, M., Lori, G., Gentilini, A., Taddei, M. L., Maira, G. D., Campani, C., Recalcati, S., Invernizzi, P., Marra, F., & Raggi, C. (2020) · Cells · doi:10.3390/cells9030596 · Cited by 28
Dihydromyricetin inhibits cell proliferation, migration, invasion and promotes apoptosis via regulating miR-21 in Human Cholangiocarcinoma Cells
Chen, L., Yang, Z., Zhou, Y., Deng, Y., Jiang, P., & Tan, S. (2020) · Journal of Cancer · doi:10.7150/jca.45970 · Cited by 28
Emerging roles of long noncoding RNAs in cholangiocarcinoma: Advances and challenges
Yang, Y., Deng, X., Li, Q., Wang, F., Miao, L., & Jiang, Q. (2020) · 癌症：英文版 · doi:10.1002/cac2.12109 · Cited by 26
Impact of trimodality sampling on detection of malignant biliary strictures compared with patients with primary sclerosing cholangitis
Baroud, S., Sahakian, A. J., Sawas, T., Storm, A. C., Martin, J. A., Dayyeh, B. K. A., Topazian, M. D., Levy, M. J., Roberts, L. R., Gores, G. J., et al. (2021) · Gastrointestinal Endoscopy · doi:10.1016/j.gie.2021.11.029 · Cited by 27
Self-citation
Role of Immune Cells in Biliary Repair
Lan, T., Qian, S., Tang, C., & Gao, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.866040 · Cited by 31
Exploring the function of stromal cells in cholangiocarcinoma by three-dimensional bioprinting immune microenvironment model
Li, C., Jin, B., Sun, H., Wang, Y., Zhao, H., Sang, X., Yang, H., & Mao, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.941289 · Cited by 28
Epidemiology of cholangiocarcinoma
Turati, F., Bertuccio, P., Negri, E., & Vecchia, C. L. (2022) · Hepatoma Research · doi:10.20517/2394-5079.2021.130 · Cited by 29
Inflammation-Based Scores Predict Responses to PD-1 Inhibitor Treatment in Intrahepatic Cholangiocarcinoma
Yang, Z., Zhang, D., Zeng, H., Fu, Y., Hu, Z., Pan, Y., Chen, J., Wang, J., Zhang, Y., Zhou, Z., et al. (2022) · Journal of Inflammation Research · doi:10.2147/jir.s385921 · Cited by 30
BEX2 Suppresses Mitochondrial Activity and Is Required for Dormant Cancer Stem Cell Maintenance in Intrahepatic Cholangiocarcinoma
Tamai, K., Nakamura, M., Shibuya‐Takahashi, R., Kanno, S., Yasui, A., Mochizuki, M., Iwai, W., Wakui, Y., Abue, M., Yamamoto, K., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-78539-0 · Cited by 28
Liquid biopsy in biliary tract cancer from blood and bile samples: current knowledge and future perspectives
Arrichiello, G., Nacca, V., Paragliola, F., & Giunta, E. F. (2022) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2022.00087 · Cited by 27
FGFR2 testing in cholangiocarcinoma: translating molecular studies into clinical practice
Angerilli, V., Fornaro, L., Pepe, F., Rossi, S. M., Perrone, G., Malapelle, U., & Fassan, M. (2023) · Pathologica · doi:10.32074/1591-951x-859 · Cited by 28
Practical guidelines for molecular testing of cholangiocarcinoma in clinical practice: Italian experts’ position paper
Fassan, M., Angerilli, V., Normanno, N., Pruneri, G., Marchetti, A., Grillo, F., Tonini, G., Scarpa, A., & Rimassa, L. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2023.104224 · Cited by 28

Authors: Ilyas, S. I., Khan, S. A., Hallemeier, C. L., Kelley, R. K., & Gores, G. J.
Affiliations: Mayo Clinic (US)
Hammersmith Hospital (GB)
University of California San Francisco Medical Center (US)
Corresponding author: Gores, Gregory J.
ORCID: Ilyas, Sumera I.
Khan, Shahid A.
Hallemeier, Christopher L.
Kelley, Robin K.
Gores, Gregory J.
Venue: Nature Reviews Clinical Oncology
Publisher: Springer Science and Business Media LLC
Published: 2017-10-10
Volume: 15
Issue: 2
Pages: 95-111
ISSN: 1759-4774 (ISSN-L)
1759-4782
DOI: 10.1038/nrclinonc.2017.157
PMC: PMC5819599
OpenAlex: W2763492611
Cited by: 1,626
References: 175
Citations by year: 2026: 88 · 2025: 164 · 2024: 252 · 2023: 247 · 2022: 253 · 2021: 272 · 2020: 209 · 2019: 82 · 2018: 51 · 2017: 1
FWCI: 19.88
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.springernature.com/gp/researchers/text-and-data-mining (tdm)
www.springernature.com/gp/researchers/text-and-data-mining (vor)
Locations: Nature Reviews Clinical Oncology (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
eScholarship (California Digital Library) (submittedVersion)
Funders: Cholangiocarcinoma Foundation
National Institutes of Health
Institute of Chemistry, Chinese Academy of Sciences
National Cancer Institute (R03CA212877)
National Institute of Diabetes and Digestive and Kidney Diseases (R56DK059427, R01DK059427, P30DK084567)
Topics: Health Sciences › Medicine › Surgery › Cholangiocarcinoma and Gallbladder Cancer Studies
Health Sciences › Medicine › Surgery › Pediatric Hepatobiliary Diseases and Treatments
Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
Keywords: cholangiocarcinoma, intrahepatic cholangiocarcinoma, hilar cholangiocarcinoma, distal cholangiocarcinoma, pathogenesis, surgical resection, liver transplantation, neoadjuvant chemoradiotherapy, locoregional chemotherapy, external beam radiotherapy, genetic landscape, molecular targets, precision medicine, immunotherapy, tumor stroma, biomarkers
MeSH terms: Adult, Cell Differentiation, Humans, Liver Neoplasms, Prognosis, Liver Transplantation, Cholangiocarcinoma, Neoadjuvant Therapy, Precision Medicine, Molecular Targeted Therapy, Chemoradiotherapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Cholangiocarcinoma — evolving concepts and therapeutic strategies

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks